treatment for kras g12c mutated nsclc with high tumor mutational burden -case-based panel discussion
Published 1 year ago • 124 plays • Length 7:44Download video MP4
Download video MP3
Similar videos
-
4:13
sotorasib vs. adagrasib as treatment for kras g12c mutated nsclc - case based panel discussion
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
2:56
barriers to drug development for kras g12c nsclc - targeted therapies in lung cancer 2023
-
12:25
adagrasib for previously treated kras g12c nsclc - asco lung review 2022
-
3:56
kras g12c inhibitors versus chemotherapy in second line - targeted therapies in lung cancer 2023
-
5:26
asco 2021 lung recap: codebreak 100: sotorasib in kras g12c mutation
-
3:59
grace targeted therapies lung cancer 2021 - treatment options available for kras k12c mutation?
-
2:45
kras mutations in advanced nsclc - 2022 program: targeted therapies forum - english
-
4:52
treatment strategies for kras nsclc - lcvl 2023
-
4:04
challenges of targeted kras treatment & current treatments - targeted therapies in lung cancer 2023
-
2:40
krystal 7 study: adagrasib /- pembrolizumab for kras g12c nsclc -targeted therapies in lung cancer
-
7:39
chemotherapy and immunotherapy for patients with kras mutations - asco lung review 2022
-
4:40
ntrk nsclc: treatment options and side effects - targeted therapies in lung cancer 2023
-
3:09
grace targeted therapies lung cancer 2021 - best treatment patient with a designated kras mutation
-
10:03
kras nsclc: details and diagnosis - targeted therapies in lung cancer 2023
-
3:02
the future of ret nsclc treatment - targeted therapies in lung cancer 2023
-
5:52
case based panel discussion - egfr - exon 20 mutation, treatment, targeted therapy, clinical trials